ADXS: Ayala Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ADXS: Ayala Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) -24.42
Book Value / Share n/a
Price / Book n/a
NCAV ($M) -33.47
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -6.19
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.30
Current Ratio 0.30

Balance Sheet (mrq) ($M)
Current Assets 7.53
Assets 16.58
Liabilities 41.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.01
Operating Income -35.27
Net Income -48.07
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -29.48
Cash from Investing 5.95
Cash from Financing 26.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Redmile Group, LLC 1.90 -36.51
02-12 13D/A Israel Biotech Fund I, L.P. 71.63 -9.75
02-12 13G/A Schindel Yair Chaim 1.31 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One)
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-23 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-16 100 4,866 2.06
2024-04-15 19 6,112 0.31

(click for more detail)

Similar Companies
ACORQ – Acorda Therapeutics, Inc. ACUR – Acura Pharmaceuticals, Inc.
ACUT – AccuStem Sciences, Inc. AFFY – Affymax, Inc.
AGRX – Agile Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Advaxis